

Cancer Stem Cells

Vismodegib

A hedgehog signaling antagonist that induces apoptosis in pancreatic cancer stem cells.¹ Medulloblastoma and basal-cell carcinoma stem cells have also been targeted by this reagent.^{2,3}

Product No: 10-2182 5 mg/ 25mg/

ML-239

Cancer stem cells (CSC) are resistant to standard cancer treatments. ML-239 was discovered in a screen using CSC-like cells created by inducing human breast epithelial cells into an epithelial-to-mesenchymal transdifferentiated state. ML-239 was found to be selectively toxic to these cells (IC₅₀= 1.2 μM).⁴

Product No: 10-1417 5 mg/ 25 mg/

Cyclopamine

Cyclopamine has been shown to deplete stem-like cancer cells in glioblastoma.⁵ Inhibition of Hedgehog signaling impaired CML stem cell growth.⁶

Product No: 10-1082 5 mg/ 25 mg/

DAPT

DAPT inhibited self-renewal and stem-ness maintenance of ovarian cancer stem-like cells.⁷ Breast cancer stem cell activity was reduced via inhibition of Notch activity.⁸

Product No: 10-4514 5 mg/ 25 mg/

Niclosamide

Niclosamide, which induces autophagic cell death, has also been identified as an inhibitor of breast cancer stem-like cells.⁹

Product No: 10-2474 1 g/ 5 g/

Salinomycin Na

A novel cancer stem cell killer which inhibits proliferation and induces apoptosis in breast cancer stem cells.¹⁰ Acts synergistically with metformin to effectively promote cell death in a variety of non-small cell lung cancer cell lines.¹¹

Product No: 10-2654 5 mg/ 25 mg/

Artesunate

Induces mitochondrial dysfunction that selectively inhibits cancer cell stem-ness of induced cancer stem-like cells.¹²

Product No: 10-2411 100 mg/ 500 mg/

Napabucasin


Inhibits cancer cell stemness gene expression and blocks spherogenesis of stemness-high cancer cells isolated from a variety of cancer types.¹³

Product No: 10-3442 5 mg/ 25 mg/


BRD 7116

Inhibits leukemia stem cells with >100-fold selectivity over normal hematopoietic stem cells.¹⁴

Product No: 10-1616 5 mg/ 25 mg/



Vismodegib



DAPT

REFERENCES

1. Singh, *et al.* 2011 PLoS One **6** e27306
2. Rudin, *et al.* 2009 N.Engl.J.Med. **361** 1173
3. Von Hoff *et al.* 2009 N.Engl.J.Med. **361** 1164
4. Carmody, *et al.* 2012 J. Biomol. Screening **17** 1204
5. Bar, *et al.* 2007 Stem Cells **25** 2524
6. Zhou, *et al.* 2009 Nature **458** 776
7. Jiang, *et al.* 2011 Chin.J.Cancer Res. **23** 140
8. Harrison *et al.* 2010 Cancer Res. **70** 709
9. Wang *et al.* 2013 PLoS One **8** e74538
10. Lu *et al.* 2015 Chem. Biol. Interact. **228** 100
11. Xiao *et al.* 2014 Oncotarget. **5** 12877
12. A Subedi *et al.* 2016 Biochem. Biophys. Res. Commun. **477** 737
13. Li *et al.* 2015 PNAS **112** 1839
14. Hartwell *et al.* 2013 Nat. Chem. Biol. **9** 840